Synergy IB Investment

Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

SnackFever Inc. is a subscription-based e-commerce company based in Los Angeles, California, that specializes in delivering a variety of snacks, candies, drinks, and ramen products to customers across the United States. Founded in 2015, SnackFever focuses on providing unique and popular treats that cater to the tastes of its subscribers, contributing to the growing interest in global snack culture. The company aims to create a community around its offerings, drawing inspiration from the global Hallyu wave, which emphasizes the enjoyment of Korean culture and products.

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.